Dako, an Agilent Technologies Company, and Cell Signaling Technology announce partnership within companion diagnostics
12 Enero 2015 - 8:00AM
Business Wire
Dako, an Agilent Technologies company and a worldwide
provider of cancer diagnostics, and Cell Signaling Technology
(CST), a worldwide provider of antibodies, today announced that
they have entered into a strategic partnership to supply antibodies
for use in Dako-branded companion diagnostics products.
"We are pleased to work with CST in the development of
high-quality, cutting-edge companion diagnostic products that will
be an important tool in the diagnosis and treatment of cancer,"
said Jacob Thaysen, president of Agilent's Diagnostics and Genomics
Group.
The market for companion diagnostics is steadily growing, as
personalized medicine may improve patient care and assist in
managing healthcare costs by targeting treatments to individuals
more likely to benefit from specific therapies, particularly in the
treatment of cancer.
Today’s announcement follows several other collaborative
agreements in the companion diagnostics area. Agilent’s Dako
business has a record of successful long-term partnerships with
companies such as Pfizer, AstraZeneca, Bristol-Myers Squibb, Merck
& Co., Amgen and Eli Lilly, and it continues to attract new
partners.
“CST recognizes that companion diagnostic products have great
potential to improve the way we diagnose and treat patients with
cancer,” said Michael J. Comb, CEO of CST. “We believe this
partnership will allow our products to contribute to the
advancement of personalized medicine.”
The financial details of the agreement were not disclosed.
About Cell Signaling Technologies
Founded by research scientists in 1999, CST is a private,
family-owned company with over 400 employees worldwide. Active in
the field of applied systems biology research, particularly as it
relates to cancer, CST understands the importance of using
antibodies with high levels of specificity and lot-to-lot
consistency. We produce all of our antibodies in house, and perform
painstaking validations for multiple applications. Technical
support is provided by the same CST scientists who produce our
antibodies, helping customers design experiments, troubleshoot, and
achieve reliable results. CST is certified by BSI to be compliant
with ISO 9001:2008 for the design, development, and production of
monoclonal antibodies. Information about CST is available at
www.cellsignal.com.
About Agilent Technologies
Agilent Technologies Inc. (NYSE: A), a global leader in life
sciences, diagnostics and applied chemical markets, is the premier
laboratory partner for a better world. Agilent works with customers
in more than 100 countries, providing instruments, software,
services and consumables for the entire laboratory workflow.
Agilent generated revenues of $4.0 billion in fiscal 2014. The
company employs about 12,000 people worldwide. In 2012, Agilent
acquired Dako, a well-known provider of reagents, instruments,
software and expertise to make accurate diagnoses and determine the
most effective treatment for cancer patients. Information about
Agilent is available at www.agilent.com and information about Dako
products is available at www.dako.com.
Cell Signaling Technology®, and CST™ are trademarks of Cell
Signaling Technology, Inc.
AgilentMaia Fredtoft Søchting, +45 2546
1083maia.sochting@agilent.comorCell Signaling Technology,
Inc.Rebecca J. Reppucci, MBA, +1 978-867-2382Director of Marketing
Communicationsmarketingpr@cellsignal.com
American Oil & Gas Common Stock (NYSE:AEZ)
Gráfica de Acción Histórica
De Ago 2024 a Sep 2024
American Oil & Gas Common Stock (NYSE:AEZ)
Gráfica de Acción Histórica
De Sep 2023 a Sep 2024